What GIP Stands For in Tirzepatide — and Why It Changes Everything

What glucose-dependent insulinotropic polypeptide actually does in the body

GIP is released by specialised cells in the small intestine within minutes of a meal. Its original, well-understood job is to tell the pancreas to release insulin in proportion to rising blood glucose, the "glucose-dependent" part of the name means insulin is only triggered when glucose levels are already elevated, which reduces the risk of a blood-sugar crash. That property matters clinically.

GIP also acts on fat tissue. It promotes the storage of fat after a meal and, in a fasted state, may encourage the release of stored fat for energy. For decades, researchers assumed this fat-storage action made GIP a poor target for a weight-loss drug. The evidence from tirzepatide's clinical programme challenged that assumption. When the GIP receptor is activated alongside GLP-1, the combined effect on appetite, food intake and energy balance appears to be greater than either pathway alone, which is the scientific argument for a dual agonist. You can read more about the mechanism in detail on our page covering how GIP works in tirzepatide.

One misconception worth setting aside gently: some people assume GIP in tirzepatide is simply a minor add-on to the GLP-1 action. The trial data suggest it contributes meaningfully to the overall effect, though the precise weighting of each pathway in humans is still an active area of research, and our tirzepatide GIP page explores what the current science says about that contribution. The NHS medicines information for tirzepatide describes it as a dual agonist that works by regulating both appetite and blood-sugar control through these two receptors. [NHS: tirzepatide medicines information]

What the SURMOUNT-1 findings tell us about dual GIP/GLP-1 activation

The SURMOUNT-1 trial, published in the New England Journal of Medicine and involving 2,539 adults with obesity, ran for 72 weeks alongside a reduced-calorie diet and increased physical activity. At the 15 mg maintenance dose, participants saw an average body-weight reduction of around 20–21%. That figure, and the trial design, formed a large part of the evidence base NICE used when it recommended tirzepatide for weight management in December 2024 (TA1026). [NICE TA1026: tirzepatide for weight management]

For comparison, GLP-1-only semaglutide (Wegovy) produced average reductions of around 15% over 68 weeks in its pivotal trial at 2.4 mg. The subsequent SURMOUNT-5 head-to-head study, published in the New England Journal of Medicine in 2025, found tirzepatide produced greater average weight loss than semaglutide 2.4 mg over 72 weeks in adults with obesity. Researchers attribute at least part of that difference to the additional GIP receptor activation, though the full picture is biologically complex. If you are weighing up the two medicines, our overview of tirzepatide's GLP-1 and GIP pathways goes into the comparative science further.

What the trials cannot do is predict exactly how any individual will respond. Biology, starting weight, metabolic profile and how well the lifestyle changes are sustained all affect outcomes. Results described here are trial averages, not personal guarantees.

How tirzepatide uses both receptors in practice

Tirzepatide is engineered as a single molecule that binds to both the GIP receptor and the GLP-1 receptor. It is delivered once weekly by subcutaneous injection via the Mounjaro KwikPen, starting at 2.5 mg (a dose chosen to let the body adjust gradually) and titrated by the prescriber through 5, 7.5, 10, 12.5 and up to 15 mg. The UK brand name is Mounjaro, manufactured by Eli Lilly.

The combined receptor activation works through several overlapping mechanisms: slowing gastric emptying (so food leaves the stomach more slowly and you feel full for longer), reducing appetite signals in the brain, and improving insulin sensitivity. The GIP component may also play a role in reducing nausea compared with GLP-1-only medicines, though individual experience varies considerably. Common side effects are gastrointestinal (nausea, loose stools, indigestion, constipation) typically most noticeable after starting or after a dose step, and often settling within a couple of weeks.

Understanding the receptor science is one thing; knowing whether tirzepatide is clinically appropriate for you is another matter entirely. That assessment involves your weight, health history, any other medicines you take, and conditions a prescriber needs to review. Our clinical team at nume (sorry, at our pharmacy, reviewed by a GPhC-registered Independent Prescriber) looks at exactly that picture. You can explore the full treatment context on our tirzepatide information page or read a broader summary of weight-loss treatment options. Cost is a reasonable question too; our Mounjaro price comparison guide explains what private treatment typically involves in the UK.

If you have read this far and are wondering whether tirzepatide might be right for you, the next step is a clinical assessment rather than more searching. Start your free consultation and a prescriber will review your information the same day.